Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

NIH 2 INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 17 Myeloproliferative Disorders 5 Myelodysplastic Syndromes 5 Cholangiocarcinoma 2 Biliary Tract Neoplasms 2 Pancreatic Ductal Adenocarcinoma 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Lymphoma, Follicular 1 Leukemia 1 IDH1 Mutation Myeloid Neoplasms 1 Hematologic Neoplasms 1 Glioma 1 Chondrosarcoma 1 Anemia, Refractory, with Excess of Blasts 1 AML 1

Interventions

Temozolomide 109 Magnetic Resonance Spectroscopy 52 Bevacizumab 52 Radiotherapy 44 Irinotecan 27 Blood Specimen Collection 19 Surgical Procedures, Operative 16 Radiation 15 Aminolevulinic Acid 15 Carboplatin 13 fluorodopa F 18 12 Nivolumab 12 Radiotherapy, Intensity-Modulated 11 Carmustine 11 Radiosurgery 10 Magnetic Resonance Imaging 10 pembrolizumab 9 Topotecan 9 Specimen Handling 9 Everolimus 9 Erlotinib Hydrochloride 9 Biopsy 9 poly ICLC 8 Surveys and Questionnaires 8 Standard of Care 8 Etoposide 8 Drug Therapy 8 Lomustine 7 Filgrastim 7 Cyclophosphamide 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Glioma × ivosidenib × Clear all

NCT04056910 2025-02-27

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

University of Pittsburgh

Phase 2 Completed

15 enrolled 14 charts

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡